CLINICAL CASE: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. CONCLUSION: Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME.
CLINICAL CASE: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. CONCLUSION: Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME.
Authors: Khalil Ghasemi Falavarjani; Mohammad-Mehdi Parvaresh; Mehdi Modarres; Masih Hashemi; Nasrollah Samiy Journal: J Ophthalmic Vis Res Date: 2012-07
Authors: Vinodh Kakkassery; Tim Schultz; Marc Ilan Wunderlich; Marc Schargus; H Burkhard Dick; Jörg Rehrmann Journal: J Ophthalmol Date: 2017-12-19 Impact factor: 1.909